Clinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals

Reuters05:54

Clinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals

Clinuvel outlined its program for the American Academy of Dermatology Annual Meeting in Denver, held March 27–31.
Company activities at the meeting covered afamelanotide development for vitiligo and its SCENESSE program for erythropoietic protoporphyria.
A proprietary AI-based Vitiligo Visual Algorithm tool was presented, and it is being used alongside the CUV105 vitiligo study.
Plans were stated to include the tool in the protocol for the upcoming CUV107 Phase III vitiligo study.
Clinuvel participated in three satellite symposia on March 26, including meetings hosted by the Photodermatology Society, the Global Vitiligo Foundation, and the Skin of Color Society.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622894932?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 05:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622894932","market":"us","top_or_hot":-1,"title":"Clinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Clinuvel outlined its program for the American Academy of Dermatology Annual Meeting in Denver, held March 27–31.\n        </li>\n<li>\n          Company activities at the meeting covered afamelanotide development for vitiligo and its SCENESSE program for erythropoietic protoporphyria.\n        </li>\n<li>\n          A proprietary AI-based Vitiligo Visual Algorithm tool was presented, and it is being used alongside the CUV105 vitiligo study.\n        </li>\n<li>\n          Plans were stated to include the tool in the protocol for the upcoming CUV107 Phase III vitiligo study.\n        </li>\n<li>\n          Clinuvel participated in three satellite symposia on March 26, including meetings hosted by the Photodermatology Society, the Global Vitiligo Foundation, and the Skin of Color Society.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> Limited published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 05:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Clinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Clinuvel outlined its program for the American Academy of Dermatology Annual Meeting in Denver, held March 27–31.\n        </li>\n<li>\n          Company activities at the meeting covered afamelanotide development for vitiligo and its SCENESSE program for erythropoietic protoporphyria.\n        </li>\n<li>\n          A proprietary AI-based Vitiligo Visual Algorithm tool was presented, and it is being used alongside the CUV105 vitiligo study.\n        </li>\n<li>\n          Plans were stated to include the tool in the protocol for the upcoming CUV107 Phase III vitiligo study.\n        </li>\n<li>\n          Clinuvel participated in three satellite symposia on March 26, including meetings hosted by the Photodermatology Society, the Global Vitiligo Foundation, and the Skin of Color Society.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CUV.AU\">Clinuvel Pharmaceuticals</a> Limited published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CUV.AU","symbol_name":"CLINUVEL PHARMACEUTICALS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL6GH32Q:1","article_id":"2622894932","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622894932","pubTimestamp":1774562051,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Clinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals. Clinuvel outlined its program for the American Academy of Dermatology Annual Meeting in Denver, held March 27–31.Company activities at the meeting covered afamelanotide development for vitiligo and its SCENESSE program for erythropoietic protoporphyria.A proprietary AI-based Vitiligo Visual Algorithm tool was presented, and it is being used alongside the CUV105 vitiligo study.Plans were stated to include the tool in the protocol for the upcoming CUV107 Phase III vitiligo study.Clinuvel participated in three satellite symposia on March 26, including meetings hosted by the Photodermatology Society, the Global Vitiligo Foundation, and the Skin of Color Society.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inf","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CUV.AU":"CLINUVEL PHARMACEUTICALS LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"Clinuvel在丹佛AAD年会上展示白癜风和EPP项目；预计出席人数将达到20,000名专业人士","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUV.AU":0.9},"content_text":"Clinuvel showcases vitiligo and EPP programs at AAD Annual Meeting in Denver; attendance expected to reach 20,000 professionals\n    \n\n\n          Clinuvel outlined its program for the American Academy of Dermatology Annual Meeting in Denver, held March 27–31.\n        \n\n          Company activities at the meeting covered afamelanotide development for vitiligo and its SCENESSE program for erythropoietic protoporphyria.\n        \n\n          A proprietary AI-based Vitiligo Visual Algorithm tool was presented, and it is being used alongside the CUV105 vitiligo study.\n        \n\n          Plans were stated to include the tool in the protocol for the upcoming CUV107 Phase III vitiligo study.\n        \n\n          Clinuvel participated in three satellite symposia on March 26, including meetings hosted by the Photodermatology Society, the Global Vitiligo Foundation, and the Skin of Color Society.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622894932","isCrawlerRequest":true}